anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
Participants start on Liquid Tirosint®-SOL for 8 weeks using continued same daily dose of LT4. Dose adjustments are allowed as needed, based on laboratory results and clinical response. Then Participants will crossover to conventional therapy of LT4 tablets for 8 weeks. Participants total participation will be 16 weeks total.
All subjects will be asked to do everything the self-monitoring group is asked to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. Messages will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
BACKGROUND: Artemisia argyi is a traditional herbal medicine belonging to the genus Artemisia that plays an important role in suppressing inflammation. However, the chemical constituents and underlying mechanisms of its therapeutic potential in neuroinflammation are still incompletely understood, and warrant further investigation.
METHODS: Several column chromatography were employed to isolate and purify chemical constituents from Artemisia argyi, and modern spectroscopy techniques were used to elucidate their chemical structures. The screening of monomeric compounds with nitric oxide inhibition led to the identification of the most effective bioactive compound, which was subsequently confirmed for its anti-inflammatory capability through qRT‒PCR. Predictions of compound-target interactions were made using the PharmMapper webserver and the TargetNet database, and an integrative protein-protein interaction network was constructed by intersecting the predicted targets with neuroinflammation-related targets. Topological analysis was performed to identify core targets, and molecular docking and molecular dynamics simulations were utilized to validate the findings. The result of the molecular simulations was experimentally validated through drug affinity responsive target stability (DARTS) and Western blot experiments.
RESULTS: Seventeen sesquiterpenoids, including fifteen known sesquiterpenoids and two newly discovered guaiane-type sesquiterpenoids (argyinolide S and argyinolide T) were isolated from Artemisia argyi. Bioactivity screening revealed that argyinolide S (AS) possessed the most potent anti-inflammatory activity. However, argyinolide T (AT) showed weak anti-inflammatory activity, so AS was the target compound for further study. AS may regulate neuroinflammation through its modulation of eleven core targets: protein kinase B 1 (AKT1), epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein Kinase (FYN), Janus Kinase (JAK) 1, mitogen-activated protein (MAP) Kinase 1,8 and 14, matrix metalloproteinase 9 (MMP9), ras-related C3 botulinum toxin substrate 1 (RAC1), nuclear factor kappa-B p65 (RELA), and retinoid X receptor alpha (RXRA). Molecular dynamics simulations and DARTS experiments confirmed the stable binding of AS to JAK1, and Western blot experiments demonstrated the ability of AS to inhibit the phosphorylation of downstream Signal transducer and activator of transcription 3 (STAT3) mediated by JAK1.
CONCLUSIONS: The sesquiterpenoid compounds isolated from Artemisia argyi, exhibit significant inhibitory effects on inflammation in C57BL/6 murine microglia cells (BV-2). Among these compounds, AS, a newly discovered guaiane-type sesquiterpenoid in Artemisia argyi, has been demonstrated to effectively inhibit the occurrence of neuroinflammation by targeting JAK1.
PURPOSE: An organic/inorganic nanohybrid complex for preventing hair loss and promoting hair growth containing vitamin C is provided to ensure stability and to slowly release vitamin C. CONSTITUTION: A nanohybrid complex for preventing hair loss and promoting hair growth is inserted between a metal salt. The metal salt is layered double hybroxide(LDH) of metal double layer or zinc basic salt(ZBS). The LDH is denoted by structure formula (M^2+_(1-x)N^3+_X(OH)^2)A_X yH^2O. The ZBS is denoted by structural formula Zn_5(OH)_8A nH_2O or Zn_3(OH)_4A_2 nH_2O. A composition for preventing hair loss and promoting hair growth contains nanohybrid complex as an active ingredient in which vitamin C is inserted between layers. The composition is used in the form of lotion, emulsion, cream, essence, or spray.
PROBLEM TO BE SOLVED: To provide a solution preparation containing a highly pure Fuscopia obliqua (Fr.) Aoshima extract capable of being directly injected into the blood or muscle of a human body or animal body and obtained by removing or reducing unnecessary ashes, especially potassium compounds and sodium compounds, and, if necessary, other unnecessary components from a Fuscopia obliqua (Fr.) Aoshima extract. SOLUTION: This solution preparation used for injection or intravenous drip injection, or the solid preparation such as suppository or tablet contains a highly pure Fuscopia obliqua (Fr.) Aoshima extract obtained by removing ashes, especially potassium compounds and sodium compounds, from a Fuscopia obliqua (Fr.) Aoshima extract. The medicine having therapeutic activities and actions for wide various syndromes contains as an active ingredient the Fuscopia obliqua (Fr.) Aoshima extract in a state especially nor removed in the ashes. The medicine has many physiological activities such as an antiviral activity, an antitumor activity and an immunostimulating activity against AIDS, influenza and the like. Fine energies such as far IR light, minus ions and high functional water may be added.
Kidney stone is a common and highly recurrent disease in urology, and its pathogenesis is associated with various factors. However, its precise pathogenesis is still unknown. Ferroptosis describes a form of regulated cell death that is driven by unrestricted lipid peroxidation, which does not require the activation of caspase and can be suppressed by iron chelators, lipophilic antioxidants, inhibitors of lipid peroxidation, and depletion of polyunsaturated fatty acids. Recent studies have shown that ferroptosis plays a crucial role in kidney stone formation. An increasing number of studies have shown that calcium oxalate, urate, phosphate, and selenium deficiency induce ferroptosis and promote kidney stone formation through mechanisms such as oxidative stress, endoplasmic reticulum stress, and autophagy. We also offered a new direction for the downstream mechanism of ferroptosis in kidney stone formation based on the "death wave" phenomenon. We reviewed the emerging role of ferroptosis in kidney stone formation and provided new ideas for the future treatment and prevention of kidney stones.
Neuroinflammation in the central nervous system (CNS), driven largely by resident phagocytes, has been proposed as a significant contributor to disability accumulation in multiple sclerosis (MS) but has not been addressed therapeutically. Bruton's tyrosine kinase (BTK) is expressed in both B-lymphocytes and innate immune cells, including microglia, where its role is poorly understood. BTK inhibition may provide therapeutic benefit within the CNS by targeting adaptive and innate immunity-mediated disease progression in MS. Using a CNS-penetrant BTK inhibitor (BTKi), we demonstrate robust in vivo effects in mouse models of MS. We further identify a BTK-dependent transcriptional signature in vitro, using the BTKi tolebrutinib, in mouse microglia, human induced pluripotent stem cell (hiPSC)-derived microglia, and a complex hiPSC-derived tri-culture system composed of neurons, astrocytes, and microglia, revealing modulation of neuroinflammatory pathways relevant to MS. Finally, we demonstrate that in MS tissue BTK is expressed in B-cells and microglia, with increased levels in lesions. Our data provide rationale for targeting BTK in the CNS to diminish neuroinflammation and disability accumulation.
A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
Lumbar disc disease may occur when a disc in the low back area of the spine bulges or herniates between the bony areas of the spine. Lumbar disk disease causes lower back pain and leg pain and weakness that is made worse by movement and activity. Lumbar disc bulge is typically managed through a multidimensional approach that integrates various therapeutic techniques aimed at reducing symptoms and enhancing functional outcomes. The use of SNAGs has been shown to produce positive results such as decreased pain levels and increased mobility in previous studies. Overall physical conditioning can be improved by using a holistic approach that consists of controlled movements combined with breathing techniques and mindfulness. In order to treat lumbar disc bulge patients more effectively, it is important to understand how use and efficacy differ when applying SNAGs alone versus together with Pilates. Delving into how combining SNAGs and Pilates affects lumbar disc bulge patients contributes to an expanding body of proof advocating for a multimodal treatment.
Two facilities will follow their local protocols for infection prevention, including COVID-19 precautions. We will swab environmental surfaces at these sites to compare outcomes.
Suvorexant binds to orexin receptors, OX1R and OX2R (Ki= 0.55 and 0.35 nM, respectively). 

Antagonism of orexin receptors may also underlie potential adverse effects such as signs of narcolepsy/cataplexy. Genetic mutations in the orexin system in animals result in hereditary narcolepsy; loss of orexin neurons has been reported in humans with narcolepsy.

Evaluation of QTc Interval

The effects of suvorexant on the QTc interval were evaluated in a randomized, placebo-, and active-controlled (moxifloxacin 400 mg) crossover study in healthy subjects (n=53). The upper bound of the one-sided 95% confidence interval for the largest placebo-adjusted, baseline-corrected QTc interval was below 10 ms based on analysis of suvorexant doses up to 240 mg, 12 times the maximum recommended dose. BELSOMRA thus does not prolong the QTc interval to any clinically relevant extent.
The invention relates to a vitamin C soluble tablet. The medicinal composition is vitamin C or calcium salt dihydrate thereof. The invention also provides a preparation method of the vitamin C soluble tablet. A reasonable auxiliary material formula is selected, so that the vitamin C soluble tablet can be quickly disintegrated within 2 minutes in water and becomes a settled solution form, so that the drug is quickly obtained. By adopting the preparation method disclosed by the invention, vitamin C can be well protected, and oxidation is reduced. Meanwhile, the preparation time is also shortened when the tablet with excellent performance is obtained, and the cost is reduced. The preparation method disclosed by the invention is simple and convenient in process, easy to carry out, and applicable to massive industrial production.
Patients with concurrent chronic ulcerative colitis and primary sclerosing cholangitis or patients with chronic ulcerative colitis and known colorectal dysplasia or cancer, presenting for surveillance colonoscopy will be recruited. After giving informed consent patients will then undergo colonoscopy in a segmental fashion. Colonoscopy with white light will be performed to the cecum and examination will be performed on withdrawal. First conventional white light will be used to examine the cecum and ascending colon and random biopsies will be obtained. All endoscopically apparent lesions will be biopsied separately. Immediately following will be examination of that segment of cecum and ascending colon under AFI first, then NBI with targeted biopsies of suspicious areas being taken. The AFI and NBI modality will be achieved by simply flipping a switch.. If necessary, washing of oozing blood from random biopsy sites will be performed., The remainder of the colon will be assessed in like fashion: transverse, descending and rectosigmoid. Because high definition endoscopy is the default modality, this will be in use throughout the procedure.

All lesions detected will be documented and biopsied for a maximum of four biopsies per suspicious lesion. Note will be taken of which modality resulted in visualization of the lesion. Data on the factors under study will be collected: i) disease type (CUC + PSC or CUC with known dysplasia), ii) Age, iii) Sex, iv) length of time with disease, v) extent of disease, vi) the interaction between iv and v will be collected. In addition, dysplasia yes/no will be established after biopsy histology is established and the modality under which abnormalities were observed will also be recorded.
PURPOSE: A producing method of plant material powder using the enzymatic treatment is provided to maintain or improve the functionality of plant materials in the original material state. CONSTITUTION: A producing method of plant material powder using the enzymatic treatment comprises the following steps: inserting water, protopectinase, and plant materials into a reactor; stirring the mixture for relaxing plant cells, and centrifugal-separating the mixture to obtain precipitates; adding water to the precipitates, and heating the mixture at 100 deg. C for 20-30 minutes for inactivating enzyme; and freeze-drying and crushing the precipitates. 0.1%(w/v) of protopectinase is mixed with other ingredients in the reactor. The pH inside the reactor is 4-6, and the temperature inside the reactor is 30-50 deg. C. [Reference numerals] (AA) Conventional way of grind-processing; (BB) Protopectinase treatment processing of this provided invention; (CC) Destroying cell membranes and cell walls; (DD) Maintaining the shape of single cells
It is the thorough consistency between the pathophysiological pattern of ischemic stroke and the haemostaseological characteristics of LD Heparin 10.5 Kd that confer specificity to the pertinent patent claim. In particular it is specific role of Tissue factor (TF) and its complex with Factor Vila respectively trigging off cerebral thrombogenesis that condition the rationale of LD Heparin in ischemic stroke. It is the TF/F Vila—complex that makes up the adequate substrate for LD Heparin which is rather resistant to the classical antithrombin-mediated influence but primarily responsive to Tissue Factor Pathway Inhibitor (TFPI). Its extraordinary release on LD Heparin in which LMWH (Enoxaparin) is exceeded threefold constitutes the rationale of striking out on the new indication of stroke. The TFPI-dependent impact is safeguarded by the controlled curtailment of anti-factor Xa activity as permissive for the inhibition of TF/F Vila, the ratios of activities between TFPI and anti-factor Xa as expressed in the AUC's of both heparins differing threefold either. It is not only that disease-centered antithrombotic effect but also the way how the risk of bleeding is tackled in general in which LD Heparin contrasts with all others in its class: Owing to the “double truncation” of the molecular spectrum i.e. through the curtailment of its low and very long molecular species major sources of bleeding are excluded. The inventory of auxiliary properties in particular the adequate pharmacokinetics, the trimmed peak blood levels, the lack of plasmatic accumulation in age-dependent decline of renal function and renal insufficiency, the availability of valid and sensitive monitoring (APTT), and last but not least the prompt and complete reversibility of the anticoagulatory effect as contrasted to LMWH substantiates the indication-specific profile. On the whole the multipronged refinements of LD Heparin are aiming at a heightened benefit-risk-ratio (“therapeutic window”) which takes specific shape in cerebral thrombosis. The patent claim associated reads: LD Heparin 10.5 Kd ( 10 -IIKd) for the treatment and secondary prevention of ischemic stroke. The patent claim associated reads: LD Heparin 10.5 Kd (10-11 Kd) for the treatment and secondary prevention of ischemic stroke.
Latino adolescents are at high risk for contracting HIV/AIDS. Few individual and even fewer parent interventions have been developed to address this persistent problem. Parent communication interventions provide an opportunity to enhance individual adolescent based approaches. However, there is a need for theory and culture based interventions focused on Latino parents. The program implemented in this study was designed for parents, to indirectly help reduce the health risks of their adolescents, including unintended pregnancy and STDs, including HIV/AIDS. The study has three aims regarding the examination of whether the computer based parental communication intervention is 1) associated with a greater increase in parents' comfort with, and quantity of communication; 2) associated with a greater increase in adolescents' intentions to abstain from sex and/or avoid unprotected intercourse and decreased self-reported intercourse and unprotected intercourse; and 3) feasible and acceptable to Spanish dominant Latino parents and their adolescent children.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a cassia twig-monkshood decoction, wherein the raw materials of active ingredients comprise: 9 parts by weight of cassia twig, 9 parts by weight of Chinese herbaceous peony, 9 parts by weight of ginger, 3 parts by weight of Chinese-date, 6 parts by weight of licorice, and 6 parts by weight of monkshood. The production process of the integrated new formulation comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of cassia twig-monkshood decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of cassia twig-monkshood decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of cassia twig-monkshood decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Patients receive recombinant Flt3 ligand IT on days 1-5 and also receive pembrolizumab (IV), tocilizumab (SC) as well as undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
INTRODUCTION: The worldwide prevalence of periodontitis is considerably high, and its pathogenic mechanisms must be investigated and understood in order to improve clinical treatment outcomes and reduce the disease prevalence and burden. The exacerbation of the host immune system induced by oral microbial dysbiosis and the subsequent tissue destruction are the hallmarks of the periodontitis. However, the oral bacteria involved in periodontitis are not fully understood. We used the Oxford Nanopore Technologies (ONT) sequencing system to analyze metagenomic information in subgingival dental plaque from periodontitis and non-periodontitis patients. The number of Lactobacillus zeae (L. zeae) in the periodontitis patients was 17.55-fold higher than in the non-periodontitis patients, suggesting that L. zeae is a novel periodontitis-associated pathogen. Although several Lactobacillus species are used in vivo as probiotics to treat periodontitis and compete with Porphyromonas gingivalis (P. gingivalis), the roles of L. zeae in periodontitis progression, and the relationship between L. zeae and P. gingivalis needs to be investigated.
METHODS: Both L. zeae and P. gingivalis were inoculated in the ligature-implant site of periodontitis mice. We collected mouse gingival crevicular fluid to analyze inflammatory cytokine secretion using a multiplex assay. Intact or sliced mouse maxilla tissue was used for micro-computed tomography analysis or hematoxylin and eosin staining, immunohistochemistry, and tartrate-resistant acid phosphatase staining to evaluate alveolar bone loss, neutrophil infiltration, and osteoclast activation, respectively.
RESULTS: We observed that L. zeae competed with P. gingivalis, and it increased inflammatory cytokine secretion at the ligature-implant site. Similar to P. gingivalis, L. zeae promoted ligature-induced neutrophile infiltration, osteoclast activation, and alveolar bone loss.
DISCUSSION: We, therefore, concluded that L. zeae accelerated the progression of periodontitis in the ligature-induced periodontitis mouse model.
Hirsutism is a relatively common disorder which affects approximately 5% to 15% of women. It is defined by excessive growth of terminal hair in women, which primarily affects areas dependent on androgens, such as the face, abdomen, buttocks, and thighs. Hirsutism can be caused by a variety of etiologies, which are most often not lifethreatening. However, in some cases, hirsutism can be an indicator of more serious underlying pathology, such as a neoplasm, which may require further elucidation with imaging. Within the abdomen and pelvis, adrenal and ovarian pathologies are the primary consideration. The goal of this manuscript is to review the etiologies and imaging features of various intra-abdominal and intra-pelvic causes of hirsutism.